Hyperlipidemia-Pipeline Review, H1 2015

Hyperlipidemia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6148IDB
  • |
  • Pages: 139
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hyperlipidemia-Pipeline Review, H1 2015


Global Markets Direct's, 'Hyperlipidemia-Pipeline Review, H1 2015', provides an overview of the Hyperlipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Hyperlipidemia Overview 11

Therapeutics Development 12

Pipeline Products for Hyperlipidemia-Overview 12

Pipeline Products for Hyperlipidemia-Comparative Analysis 13

Hyperlipidemia-Therapeutics under Development by Companies 14

Hyperlipidemia-Therapeutics under Investigation by Universities/Institutes 17

Hyperlipidemia-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Hyperlipidemia-Products under Development by Companies 22

Hyperlipidemia-Products under Investigation by Universities/Institutes 25

Hyperlipidemia-Companies Involved in Therapeutics Development 26

Ahn-Gook Pharmaceutical Co., Ltd. 26

Alnylam Pharmaceuticals, Inc. 27

Amgen Inc. 28

BCWorld Pharm Co. Ltd. 29

Catabasis Pharmaceuticals, Inc. 30

CJ CheilJedang Corp. 31

CrystalGenomics, Inc. 32

Daewoong Pharmaceutical Co., Ltd. 33

Eli Lilly and Company 34

Esperion Therapeutics, Inc. 35

HanAll Biopharma Co., Ltd. 36

Hanmi Pharmaceuticals, Co. Ltd. 37

Huons Co., Ltd. 38

Isis Pharmaceuticals, Inc. 39

Jeil Pharmaceutical Co., Ltd. 40

LG Life Sciences, Ltd. 41

Michigan Life Therapeutics, LLC 42

Pfizer Inc. 43

Pharmena SA 44

Piramal Enterprises Limited 45

Prometheon Pharma, LLC 46

Protalix BioTherapeutics, Inc. 47

Regeneron Pharmaceuticals, Inc. 48

TSH Biopharm Corporation Limited 49

Yuhan Corporation 50

Hyperlipidemia-Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Combination Products 52

Assessment by Target 53

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

(atorvastatin calcium + losartan potassium)-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

(atorvastatin calcium + metformin)-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

(gemigliptin + rosuvastatin calcium)-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

(rosuvastatin calcium + metformin SR)-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

(rosuvastatin calcium + telmisartan)-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

AGSAA-010-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ALN-ANG-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

BCWPC-001-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

bempedoic acid-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

bococizumab-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

BSN-272-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

CAT-2000 Series-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

CAT-2003-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

CG-301269-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

CSN-501-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Drugs to Inhibit TRIP-Br2 for Metabolic Disorders-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

DWJ-1330-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

DWJ-1351-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

etanercept biosimilar-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

evolocumab-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

gemcabene calcium-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

HCP-1007-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

HU-012-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

ISIS-ANGPTL3Rx-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

JLP-1302-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

JLP-1401-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

LY-3015014-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

microRNA-30c for Hyperlipidemia and Atherosclerosis-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

N-11-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

P-7435-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

PF-06427878-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

REGN-1001-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

S-0101870-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Small Molecule for Hyperlipidemia-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Small Molecule for Type 2 Diabetes and Hyperlipidemia-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

TRIA-662-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

Hyperlipidemia-Recent Pipeline Updates 106

Hyperlipidemia-Dormant Projects 123

Hyperlipidemia-Discontinued Products 129

Hyperlipidemia-Product Development Milestones 130

Featured News & Press Releases 130

Nov 18, 2014: Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 130

Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 132

Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia 135

Mar 05, 2014: Esperion Therapeutics Provides ETC-1002 Program Update 135

Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 136

Mar 19, 2010: FDA warns about increased risk of muscle injury with Zocor. 136

Mar 27, 2003: Zocor selected as sole high-potency HMG agent for U.S. Department of Veteran Affairs and Department of Defense. 136

Nov 05, 1998: Merck announces get-to-goal guarantee for patients taking cholesterol-lowering drug Zocor 136

Jul 05, 1995: FDA clears Merck's Zocor to save lives, prevent heart attacks; Zocor is first cholesterol-lowering drug available for this use 137

Appendix 138

Methodology 138

Coverage 138

Secondary Research 138

Primary Research 138

Expert Panel Validation 138

Contact Us 138

Disclaimer 139

List of Tables

Number of Products under Development for Hyperlipidemia, H1 2015 12

Number of Products under Development for Hyperlipidemia-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Hyperlipidemia-Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 26

Hyperlipidemia-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 27

Hyperlipidemia-Pipeline by Amgen Inc., H1 2015 28

Hyperlipidemia-Pipeline by BCWorld Pharm Co. Ltd., H1 2015 29

Hyperlipidemia-Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 30

Hyperlipidemia-Pipeline by CJ CheilJedang Corp., H1 2015 31

Hyperlipidemia-Pipeline by CrystalGenomics, Inc., H1 2015 32

Hyperlipidemia-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 33

Hyperlipidemia-Pipeline by Eli Lilly and Company, H1 2015 34

Hyperlipidemia-Pipeline by Esperion Therapeutics, Inc., H1 2015 35

Hyperlipidemia-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 36

Hyperlipidemia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 37

Hyperlipidemia-Pipeline by Huons Co., Ltd., H1 2015 38

Hyperlipidemia-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 39

Hyperlipidemia-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 40

Hyperlipidemia-Pipeline by LG Life Sciences, Ltd., H1 2015 41

Hyperlipidemia-Pipeline by Michigan Life Therapeutics, LLC, H1 2015 42

Hyperlipidemia-Pipeline by Pfizer Inc., H1 2015 43

Hyperlipidemia-Pipeline by Pharmena SA, H1 2015 44

Hyperlipidemia-Pipeline by Piramal Enterprises Limited, H1 2015 45

Hyperlipidemia-Pipeline by Prometheon Pharma, LLC, H1 2015 46

Hyperlipidemia-Pipeline by Protalix BioTherapeutics, Inc., H1 2015 47

Hyperlipidemia-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 48

Hyperlipidemia-Pipeline by TSH Biopharm Corporation Limited, H1 2015 49

Hyperlipidemia-Pipeline by Yuhan Corporation, H1 2015 50

Assessment by Monotherapy Products, H1 2015 51

Assessment by Combination Products, H1 2015 52

Number of Products by Stage and Target, H1 2015 54

Number of Products by Stage and Mechanism of Action, H1 2015 56

Number of Products by Stage and Route of Administration, H1 2015 58

Number of Products by Stage and Molecule Type, H1 2015 60

Hyperlipidemia Therapeutics-Recent Pipeline Updates, H1 2015 106

Hyperlipidemia-Dormant Projects, H1 2015 123

Hyperlipidemia-Dormant Projects (Contd..1), H1 2015 124

Hyperlipidemia-Dormant Projects (Contd..2), H1 2015 125

Hyperlipidemia-Dormant Projects (Contd..3), H1 2015 126

Hyperlipidemia-Dormant Projects (Contd..4), H1 2015 127

Hyperlipidemia-Dormant Projects (Contd..5), H1 2015 128

Hyperlipidemia-Discontinued Products, H1 2015 129

List of Figures

Number of Products under Development for Hyperlipidemia, H1 2015 12

Number of Products under Development for Hyperlipidemia-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 51

Assessment by Combination Products, H1 2015 52

Number of Products by Top 10 Targets, H1 2015 53

Number of Products by Stage and Top 10 Targets, H1 2015 53

Number of Products by Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Top 10 Routes of Administration, H1 2015 57

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 57

Number of Products by Top 10 Molecule Types, H1 2015 59

Number of Products by Stage and Top 10 Molecule Types, H1 2015 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Ahn-Gook Pharmaceutical Co., Ltd.

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

BCWorld Pharm Co. Ltd.

Catabasis Pharmaceuticals, Inc.

CJ CheilJedang Corp.

CrystalGenomics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Eli Lilly and Company

Esperion Therapeutics, Inc.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Huons Co., Ltd.

Isis Pharmaceuticals, Inc.

Jeil Pharmaceutical Co., Ltd.

LG Life Sciences, Ltd.

Michigan Life Therapeutics, LLC

Pfizer Inc.

Pharmena SA

Piramal Enterprises Limited

Prometheon Pharma, LLC

Protalix BioTherapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

TSH Biopharm Corporation Limited

Yuhan Corporation

Hyperlipidemia Therapeutic Products under Development, Key Players in Hyperlipidemia Therapeutics, Hyperlipidemia Pipeline Overview, Hyperlipidemia Pipeline, Hyperlipidemia Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com